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LiverTransplantation

Reexamining the Association of Body Mass
Index With Overall Survival Outcomes After
Liver Transplantation
Su-Hsin Chang, PhD,1 Xiaoyan Liu, MS,2 Nils P. Carlsson, BS,1 Yikyung Park, ScD,1 Graham A. Colditz, PhD,1
Jacqueline M. Garonzik-Wang, MD,3 William C. Chapman, MD,3 Jason R. Wellen, MD,3 Maria B. Doyle, MD,3
and Tarek Alhamad, MD4

Background. Several studies have shown that obese patients undergoing liver transplantation (LT) have an increased risk of
mortality regardless of Model of End Stage Liver Disease (MELD) scores. The purpose of this study is to identify the range of body
mass index (BMI) at LTassociated with the lowest risks of posttransplant mortality by MELD category. Methods. A retrospective
cohort of patients aged 18 years or older from the Organ Procurement and Transplantation Network database undergoing LT between February 27, 2002, and December 31, 2013, was identified and followed up through March 14, 2014. Patients' MELD
score at the time of transplantation was categorized into 10 or lower (MELD1), 11 to 18 (MELD2), 19 to 24 (MELD3), and 25 or
higher (MELD4). Multivariable adjusted Cox proportional hazard analyses were conducted. Results. Among 48 226 patients
in the analytic cohort (14.8% were in MELD1, 33.7% were in MELD2, 19.6% were in MELD3, and 32.0% were in MELD4),
25% died with mean follow-up of 1371 days. For MELD1, patient BMI ranging from 30 to 33 was associated with a better survival
outcome than BMI less than 30 or 33 or greater; for MELD2, BMI ranging from 28 to 37 had a better survival outcome than BMI
less than 28 or 37 or greater; for MELD3, the survival outcome improved with an increasing BMI; for MELD4, the survival outcome
was not associated with patient BMI. Conclusions. This study provides evidence that obesity in LT patients is not necessarily
associated with higher posttransplantation mortality and highlights the importance of the interaction between BMI and MELD category to determine their survival likelihood.

(Transplantation Direct 2017;3: e172; doi: 10.1097/TXD.0000000000000681. Published online 12 June, 2017.)

L

iver transplantation (LT) is the definitive treatment for
patients with end-stage liver disease. In 2015, 7127 liver
transplants were performed in the United States, making it
the second most common solid organ transplant performed
in the United States.1

Studies have shown that risk factors of post-LT mortality
include donor age, cold ischemia time, United Network for
Organ Sharing urgency status (1, 2A, 2B, or 3),2 and recipient body mass index (BMI).3‐8 For the latter, there has been
continued controversy regarding the association of recipient
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BMI and posttransplant outcomes, with multiple studies
reporting conflicting results. Some studies found that LT
recipients with extremely low BMI were associated with a
higher mortality risk9; some studies found that obese patients
or an elevated BMI were associated with a higher mortality
risk,3,4,6,9 whereas others did not find this association in
obese groups.5‐7
More than 1 in 3 US adults are obese (BMI ≥30).10 Obesity
is associated with elevated risks of morbidity and mortality,11‐14 including chronic liver disease.15,16 As a result, the
prevalence of obesity in the new LT waitlist registrant population is high.17,18 However, many transplant programs
decline LT to obese candidates17 because they have a higher
risk of perioperative and postoperative complications19,20
and death3,4,6,9 than nonobese candidates. Moreover, obese
waitlisted candidates have a longer waiting time for LT and
the likelihood of receiving a Model for End-Stage Liver Disease (MELD) exception is 30% to 38% lower than normalweight candidates.21
The objective of this study is to reexamine the relationship
between BMI and post-LT overall survival after the institution of the MELD system and determine the BMI range associated with the highest post-LT survival chance by MELD
category. The evidence provided by this study can either confirm or revert the current understanding of the association
between BMI and posttransplantation survival and inform
current clinical practice. Additionally, because BMI is a
modifiable factor, the results of this study have the potential
to inform the waitlisted candidates and their healthcare providers about the optimal BMI associated with the best survival outcomes.
MATERIALS AND METHODS
Data

A retrospective cohort of patients who underwent LT before December 31, 2013, was obtained from the Organ Procurement and Transplantation Network (OPTN) database.
We obtained both recipient and donor demographic data
on sex, race, height, weight, BMI, and age at LT. We also
collected patient clinical data on etiology of liver disease,
comorbidities, whether the patient received dialysis a week
before LT, medical conditions, the international normalized
ratio, the MELD score, ascites, level of serum albumin, serum
creatinine, and total bilirubin at LT. Additionally, LT data on
cold ischemia time, level of human leukocyte antigen mismatch, whether the recipient was on ventilator, whether the
recipient was on life support, and overall survival outcomes.
Lastly, we obtained time of graft failure, if the patient experienced one.
Exempt study approval was obtained from the
Washington University School of Medicine Institutional
Review Board.
BMI and the MELD Score

Recipient BMI was recorded at the time of LT. Data on
BMI were used when available; otherwise, it was computed
as weight (measured at LT) in kilograms divided by the
square of height in meters. MELD scores, calculated from
laboratory values as opposed to scores granted by exception
or used to determine allocation priority,22 were obtained
from the database as submitted by transplant centers.

www.transplantationdirect.com

Recipient MELD score was then categorized into the following groups: 0 to less than 11 (MELD1), 11 to less than 19
(MELD2), 19 to less than 25 (MELD3), and 25 or greater
(MELD4).22
Analytic Cohort

The analytic cohort was formed by excluding the following patients: (i) patients with previous LT; (ii) patients who
underwent simultaneous kidney transplantation with the
LT; (iii) patients receiving a liver from a deceased donor from
a cardiac death; (iv) patients with missing data on either BMI
or 1 of the height and weight; (v) patients undergoing LT before February 27, 2002, the institution of the MELD system;
(vi) patients without a MELD score.
Outcome Measures

The primary outcome was patient survival after LT.
Patients without date of death information were assumed to
be alive at the time of the last death recorded within the
cohort, March 14, 2014.
Statistical Analyses

To compare the MELD categories, χ2 tests were performed
to examine differences in proportions for categorical variables,
and analysis of variance was conducted to test the differences
in means for continuous variables. When categorical variables
were used, an unknown category was created for individuals
with missing data.
Cox proportional hazards models were used in the multivariable analyses. Adapted from the risk-adjustment models
published by the Scientific Registry of Transplant Recipients,23 we included the following covariates: recipient and
donor sex, race, BMI at LT (recipient: continuous or categorical), age at LT; recipient etiology of liver disease (fulminant,
noncholestatic cirrhosis, cholestatic cirrhosis, biliary atresia,
metabolic disease, malignant neoplasm24), status of hepatocellular carcinoma (HCC), hepatitis C, diabetes, hypertension, dialysis before LT, ascites (absent, slight, moderate),
medical conditions when treatment was performed (home,
inpatient, ICU), international normalized ratio, level of
serum albumin, serum creatinine, and total bilirubin at
LT, cold ischemia time, human leukocyte antigen mismatch,
whether the recipient was on a ventilator, on life support,
time-varying graft failure status. χ2 Tests were used to examine the statistical significance of the coefficient associated
with each covariate.
All tests are 2-sided. Statistical significance was evaluated
at the 0.05 level. All statistical analyses were performed using
SAS version 9.4 (SAS Institute Inc., Cary, NC).
Determination of BMI Associated With the Lowest
Mortality Rate After LT

Using the analytic cohort, we ran multivariable adjusted
Cox analyses and tested different functional forms of recipient BMI, including (a) the standard BMI categorization
(<18.5, 18.5 to <25 [reference], 25 to <30, 30 to <35, 35
to <40, ≥4025), (b) quasi-standard BMI categorizations
(≤25 [reference], 25.1-30, 30.1-35, 35.1-40, 40.1-50,
≥50.14; <19, 19 to <23 [reference], 23 to <25, 25- <30, 30
to <35, 35 to <40, ≥406; or <20, 20 to <25 [reference],
25 to <30, 30 to <35, 35 to <40, ≥405), (c) BMI categorization examining extreme BMI (<18.5, 18.5 to <40 [reference],
≥409 or <40 [reference], ≥403), (d) continuous BMI,
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(e) quadratic BMI, and (f ) inverse BMI.26‐28 We then selected
the functional form of BMI that provides the best model fit
statistics: both the statistical significance of the coefficient
(s) associated with BMI and the Akaike information
criterion.
For each MELD category, to determine the relationship
between BMI and mortality after LT, we repeated the same
process. In addition, for each MELD category, we performed
Cox analyses using all possible ranges of BMI between 18
and 50 one by one as the reference group to help determine
the relationship and to identify the BMI range for the best
survival outcomes of LT patients based on the statistical
significance.
Sensitivity Analyses

To ensure the robustness of our conclusion, we performed
the following sensitivity analyses. First, we excluded all patients diagnosed with HCC or with any known malignancy
reported at listing and at LT from the analytic cohort due to
the concern about weight loss and higher mortality rate not
related to LT in these patients. Second, we excluded patients
with any active MELD exception points as of LT. Lastly, we
used patient BMI at the time of listing, rather than BMI at
LT in the analyses to explore how the variation in weight impacts our conclusion.
RESULTS
We identified 115 473 patients who underwent LT before
December 31, 2013, in the OPTN database (Figure 1). We
excluded 1638 patients with previous LT. We further excluded 4807 patients who underwent simultaneous kidney
transplantation with the LT; 21 143 patients who received
liver from a deceased donor with a cardiac death; 860 patients
without data on BMI; and 28 342 patients with a LT date before February 27, 2002. Fifty-six patients without a MELD
score and 8615 patients younger than 18 years were also
excluded. Lastly, 1786 patients with missing data on any
continuous covariate or outcome variables were excluded.
The analytic cohort included 48 226 patients, among
whom, 11 976 (24.8%) died with a mean follow-up time of
1371 days (Table 1).
Among the analytic cohort, 7140 (14.8%) patients were in
MELD1, 16 230 (33.7%) patients in MELD2, 9440 (19.6%)
patients in MELD3, and 15 416 (32.0%) patients in MELD4
(Table 1). Patients in different MELD categories were
statistically different in all variables, except for donor sex
and percentage of mortality. Mean BMI increased with
MELD category (27.8 for MELD1, 28.5 for MELD2, 28.6
for MELD3, 28.8 for MELD4, P < 0.001).
Using our data and different BMI functional forms a to f,
some of which replicated the categorization from published
studies.3‐6,9 Figure 2 shows the multivariable adjusted hazard ratios (HRs) for categorical and continuous BMI to compare the HRs from our study with the HRs reported in
previous studies. Figures 2A to C demonstrated inconsistent
conclusions depending on the reference BMI category. In general, patients with extremely low BMI were associated with a
higher mortality risk with an HR ranging from 1.12 to 1.24;
in contrast, extremely high BMI (BMI ≥40) was insignificantly protective in Figures 2A to B or insignificantly
increased mortality risk in Figure 2C, depending on the
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reference group. Using continuous BMI, Figure 2D shows a
linear downward trend (HR, 0.99; 95% confidence interval
[CI], 0.989-0.996 per 1 unit increase in BMI); Figure 2E demonstrates a quadratic relation, indicating a BMI at approximately 34 kg/m2 was associated with the lowest mortality
risk; Figure 2F presents a decreasing mortality risk as BMI increases. Among A to F, the quadratic BMI had the best model
fit statistics.
Stratifying by MELD category, we plotted the HRs for
mortality against BMI in Figure 3. The quadratic BMI for
MELD1-2 and BMI for MELD3-4 were chosen based on
their Akaike information criterion and statistical significance
(see relevant statistics in Figure 3). For MELD1-2, a BMI
around 32 was associated with the lowest mortality risk.
For MELD3, mortality risk decreased by 1% with a unit
increase in BMI (HR, 0.99; 95% CI, 0.984-0.998). For
MELD4, BMI was not associated with overall mortality
(HR, 0.996; 95% CI, 0.990-1.001).
Exploring the BMI range associated with the lowest mortality risk/best survival chance after LT, we found that for
MELD1 patients, BMI less than 30 (HR, 1.27; 95% CI,
1.10-1.47) or BMI of 33 or greater (HR, 1.25; 95% CI,
1.05-1.49) was associated with a higher mortality risk after
LT than BMI of 30 to 33 (Table 2 and full results presented
in Table S2, SDC, http://links.lww.com/TXD/A40). For
MELD2, BMI less than 28 (HR, 1.15, 95% CI, 1.07-1.23)
or BMI of 37 or greater (HR, 1.22; 95% CI, 1.07-1.38)
was associated with a higher mortality risk after LT than
BMI of 28 to 37. For MELD3, higher BMI was associated
with a lower mortality risk (HR, 0.99; 95% CI, 0.9800.998 per 1 unit increase in BMI). For all MELD categories
(Table S2, SDC, http://links.lww.com/TXD/A40), older age
in both recipients (HRs, 1.01-1.02 per 1 year increase in
age) and donors (HRs, 1.01 per 1 year increase in age) and

FIGURE 1. Data attrition diagram.
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TABLE 1.

Select demographics and characteristics of 48 226 liver transplant patients and their donors
Overall
N
%
Recipient characteristics
Age (mean ± SD), ya
Female, %a
Race, %a
White
Black
Hispanic
Other
Recipient BMIa
Underweight (BMI, <18.5)
Normal weight (BMI, 18.5-24.9)
Overweight (BMI, 25-29.9)
Obese class I (BMI, 30-34.9)
Obese class II (BMI, 35-39.9)
Obese class III (BMI, ≥40)
Recipient BMI (mean ± SD), kg/m2a
Etiology of liver disease, %a
Biliary atresia
Cholestatic cirrhosis
Fulminant
Malignant neoplasm
Metabolic disease
Noncholestatic cirrhosis
HCC, %a
Yes
No
Hepatitis C, %a
Negative
Positive
Ascites at LT, %a
Absent
Slight
Moderate
Unknown
Graft failureb (P = 0.001), %
Yes
No
Follow-up duration (mean ± SD), d
Donor characteristics
Donor BMI (%)b (P < 0.001)
Underweight (BMI, <18.5)
Normal weight (BMI, 18.5-24.9)
Overweight (BMI, 25-29.9)
Obese class I (BMI, 30-34.9)
Obese class II-III (BMI, ≥35)
Unknown
Donor age (mean ± SD), ya
Female (P =0.462), %
Donor race, %a
White
Black
Hispanic
Other
Unknown

48 226
100.00
53.86 ± 9.87
30.94
72.17
9.02
12.95
5.86
1.62
27.13
35.82
22.24
9.70
3.49
28.50 ± 5.64

MELD1, 0 to < 11
7140
14.81
56.27 ± 9.20
27.31
67.45
9.01
10.88
12.66
1.75
30.31
37.62
20.59
7.80
1.93
27.82 ± 5.21

MELD2, 11 to < 19
16 230
33.65
55.13 ± 8.82
28.02
76.09
6.70
12.17
5.03
1.32
25.64
37.88
23.01
9.46
2.68
28.50 ± 5.34

MELD3, 19 to < 25
9440
19.57
53.60 ± 9.56
30.32
76.17
9.35
11.12
3.36
1.59
26.39
35.49
22.89
9.95
3.70
28.62 ± 5.66

MELD4, ≥25
15 416
31.97
51.55 ± 10.85
36.09
67.79
11.26
15.83
5.12
1.89
27.68
33.02
21.78
10.69
4.94
28.75 ± 6.09

2.75
5.11
5.06
3.51
22.03
61.52

1.96
3.24
1.44
5.76
52.98
34.62

1.95
4.84
2.29
3.06
28.48
59.37

3.24
6.48
3.43
3.20
11.41
72.24

3.67
5.43
10.64
3.15
7.41
69.70

21.08
78.92

50.15
49.85

27.63
72.37

10.74
89.26

7.03
92.97

96.36
3.64

95.62
4.38

94.89
5.11

96.32
3.68

98.26
1.74

21.99
49.52
27.81
0.69

54.45
39.79
5.15
0.60

23.41
58.77
17.23
0.6

13.14
54.54
31.51
0.81

10.88
41.20
47.17
0.75

0.64
99.36
1371 ± 1154

0.48
99.52
1309 ± 1116

0.61
99.39
1508 ± 1291

0.47
99.53
1448 ± 1157

0.84
99.16
1208 ± 1107

2.50
36.64
34.43
16.18
10.21
0.04
44.01 ± 16.10
41.42

2.49
36.02
34.48
16.18
10.78
0.04
44.70 ± 16.23
42.18

2.77
35.80
34.30
16.34
10.73
0.06
45.10 ± 16.33
41.50

2.24
36.69
34.19
16.44
10.41
0.02
44.46 ± 16.32
41.05

2.39
37.76
34.69
15.85
9.28
0.02
42.29 ± 15.51
41.21

66.94
16.75
12.61
3.67
0.02

66.86
16.74
12.13
4.26
0.01

67.99
17.42
10.91
3.67
0.02

68.31
17.53
11.01
3.11
0.04

65.04
15.57
15.62
3.76
0.02
Continued next page
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TABLE 1. (Continued)

Outcomes
Mortality
Overall death (P = 0.741), %
No. deathsa
Survival duration (mean ± SD), d

Overall

MELD1, 0 to < 11

MELD2, 11 to < 19

MELD3, 19 to < 25

MELD4, ≥25

24.83
11 976
861 ± 920

24.87
1776
918 ± 866

24.54
3983
1009 ± 971

24.92
2352
906 ± 950

25.07
3865
655 ± 832

a

Statistically significant at α = 0.05 for χ2 test or ANOVA test (P < .0001).
Statistically significant at α = 0.05 for χ2 test or ANOVA test (P < .05).
See Table S1, SDC, http://links.lww.com/TXD/A40 for all variables included in the analyses.
ANOVA, analysis of variance.

b

graft failure (HRs, 72.01-183.86) were risk factors of
mortality; in recipients, compared with white race, black
race was associated with a higher risk (HR, 1.28; 95% CI,
1.09-1.50 for MELD1; HR, 1.42; 95% CI, 1.27-1.59; for
MELD2; HR, 1.24; 95% CI, 1.09-1.42 for MELD3; and
HR, 1.30; 95% CI, 1.18-1.44 for MELD4).
In the sensitivity analyses (Table S3-S5, SDC, http://links.
lww.com/TXD/A40), both excluding patients with any
malignancy (including HCC) and excluding patients with
active exception as of LT reduced a large sample size in
MELD1-2. The analyses without cancer patients (Table S3,
SDC, http://links.lww.com/TXD/A40) provide similar results
to the main analysis for MELD1, 2, and 4, whereas the inverse association between BMI and mortality in MELD3
was not statistically significant. When excluding patients
with exception (Table S4, SDC, http://links.lww.com/TXD/
A40), only the relationship between BMI and mortality in
MELD2 maintains the statistical significance with the BMI
associated with the lowest mortality risk after LT being
approximately 33.2. Nonetheless, the relationship for each
MELD category (ie, the sign of the coefficient estimates,)
remains the same as the main analysis without reaching statistical significance. Using BMI at listing (Table S5, SDC,
http://links.lww.com/TXD/A40), rather than BMI at LT, we
found that generally the relationship between BMI and mortality preserve for MELD1-3, whereas BMI associated with
the lowest mortality shift to the right for MELD1 (35.6)
and MELD2 (34.4). For MELD4, a quadratic relation was
observed with a BMI of 39.3 associated with the lowest mortality risk after LT. However, the difference between BMI at
listing (median, 27.8; range, 10.8-72.9) and BMI at LT (median, 28.2; range, 10.0-71.6) is small with a median of 81
(range, 0-6286) days on the list (Table S6, SDC, http://links.
lww.com/TXD/A40).
DISCUSSION
We investigated the association between BMI at LT and
overall survival/mortality after LT in patients who underwent
LT between February 27, 2002, and December 31, 2013. We
found that without stratifying by MELD category, LT patients with a BMI of approximately 34 or within a range of
28 to 37 had the best survival outcome after transplantation.
When stratified by MELD category, for MELD1 patients, the
BMI range associated with the best survival outcome after LT
was 30 to 33; for MELD2 patients, this BMI range was 28 to
37; for MELD3 patients, higher BMI was associated with a

better survival outcome; for MELD4 patients, BMI was not
associated with overall survival outcome.
Past research has provided inconsistent results regarding
the association of BMI and survival outcome after LT largely
due to the choice of the reference BMI category, a finding of
this study. Nair et al4 analyzed the relationship of BMI and
the 2-year overall survival outcome in 23 675 patients who
underwent LT between 1988 and 1996 in the OPTN database and found that morbid obesity (BMI, 40.1-50) was an
independent predictor, compared with nonobese (BMI,
≤25) (odds ratio, 1.52; 95% CI, 1.05-2.22). Using the same
database, Rustgi et al6 studied 32 512 patients undergoing
LT between 1992 and 2000 and found that patients with a
BMI of 40 or greater had 19.7% higher mortality risk and
patients with a BMI less than 19 had 12.9% higher risk than
patients with a BMI of 19 to 22. However, patients with a
BMI of 25 to 34 had a significantly (9.9-11.7%) lower mortality
risk than patients with a BMI of 19 to 22. Similarly, Pelletier and
colleagues5 used BMI of 20 to less than 25 as the reference
group in 4488 LT recipients from 2001 to 2004 and found a
protective trend in BMI of 25 to less than 30 (HR, 0.92; 95%
CI, 0.77-1.10) and BMI of 30 to less than 35 (HR, 0.84; 95%
CI, 0.68-1.03), but not in BMI of 35 or greater.
Using the same database but only restricting to patients
who underwent LT after the implementation of the MELD
system, in replicating their BMI categorizations, our study
did find a protective effect for patients with an elevated
BMI with statistical significance depending on the defined
reference BMI. Henceforth, the conclusion is likely to be
driven by the predetermined reference group. After testing
these different categorizations, our study revealed that the relationship between BMI and survival after LT was not linear.
The relationship between BMI at LT and overall mortality
risk should be quadratic with the nadir at a BMI of approximately 34. In other words, a reference BMI category defined
approximately 34, for example, 28 to 37, would yield the
lowest mortality risk. However, after stratifying by the
MELD category, this quadratic relationship only maintained
in patients with a lower MELD score (<19). For patients with
a MELD score of 19 to less than 25, the mortality risk decreased with BMI, whereas no association between BMI
and overall mortality was found for patients with a MELD
score of 25 or greater. The interactions between BMI and
MELD on post-LT mortality in patients with a lower MELD
score were also confirmed by Bambha and colleagues.29
Analyzing patients undergoing LT between 2002 and 2011
in OPTN database, Bambha et al29 found that for patients
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FIGURE 2. HRs corresponding to different categorizations and forms of BMI.

with a low MELD score (≤26), underweight (BMI <18.5) patients have an increased risk of 1-year mortality than their
normal weight (BMI, 18.5-24.9) counterparts, which partially explain our findings.
Our finding on overweight (BMI 25 to < 30) and even class
I and II obesity (BMI 30 to < 40) at LT being associated with a
lower overall mortality risk for LT recipients with a lower

MELD score is not uncommon for older people or people
with severe health conditions, termed as obesity paradox.30,31 For the association of BMI and mortality risk in
older populations, obesity paradox was found in many studies.32-39 For population with severe health conditions, obesity
paradox was found in people undergoing hemodialysis,30,40
people experiencing heart failure,41 and cancer survivors.42-45

© 2017 Wolters Kluwer
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FIGURE 3. Relationship between mortality risks and BMI by MELD category HRs were obtained by standardizing hazard rates at various
levels of BMI to hazard rates at BMI of 32 (HR, 1 at BMI of 32).

The underlying rationales of obesity paradox can be the following. First, weight loss is associated with disease progression at diagnosis or before treatments; therefore, the
association of the baseline BMI and mortality is confounded
by disease progression or other unmeasured comorbidities.
Second, people with a higher BMI had better treatment tolerance, improving survival. While our study cannot completely

TABLE 2.

Deaths after LT and selected results of multivariable adjusted
HRs for death stratified by the MELD category
BMI

Deaths after LT/n

Overall (n = 48 226)
<28
6368/24 769
28- < 37
4641/19 577
≥37
967/3880
MELD1, 0 to < 11 (n = 7140)
<30
1271/4975
30 to < 33
213/1007
≥33
292/1158
MELD2, 11 to < 19 (n = 16 230)
<28
2101/8294
28 to < 37
1579/6806
≥37
303/1130
MELD3, 19 to < 25 (n = 9440)
Continuous
2352/9440
MELD4, ≥25 (n = 15 416)
Continuous
3865/15 416
a

(%)

P

HRb

(25.71)
(23.71)
(24.92)

<0.001a

1.12

(25.55)
(21.15)
(25.22)

0.013a

(25.33)
(23.20)
(26.81)

0.002a

(24.92)

—

0.991

0.984

0.998

(25.07)

—

0.996

0.990

1.001

1.10
1.27
1.25
1.15
1.22

95% CI
1.08
1.17
Reference
1.03
1.18
1.10
1.47
Reference
1.05
1.49
1.07
1.23
Reference
1.07
1.38

Statistically significant at α = 0.05 for χ test.
All HRs were multivariable adjusted. Please see Table S2, SDC, http://links.lww.com/TXD/A40 for full
results.
b

2

rule out the potential confounding due to unmeasured or
unknown factors, our study has minimized it by controlling
for all possible factors in the data, including comorbidities
and MELD scores. Therefore, our findings on the association
of BMI and mortality risk should be mostly explained by the
second rationale.
We need to note that our conclusion does not intend to
encourage obesity. Obesity is a risk factor of liver disease
of metabolic origin,46 including nonalcoholic fatty liver
disease, cirrhosis, and HCC, all of which could progress
to liver failure requiring a LT. Because obesity is prevalent
in the United States and other countries, the prevalence
of nonalcoholic fatty liver disease is estimated to be 20%
to 30% in western countries and 80% to 90% in obese
adults.47 Furthermore, 35.4% LT patients aged 18 years
or older were obese in our analytic cohort, which is comparable to the national estimate (35.1%) of the prevalence of
obesity in adults aged 20 years or older.48,49 We also need
to note that obese patients after LT had a higher chance of
death from multisystem organ failure7 and cardiovascular
events.4 Nonetheless, our finding suggests that once obese
people develop liver disease, progress to a more advanced
liver disease, and become wait-listed for LT, maintaining
a high BMI may be beneficial to their overall survival after
LT, depending on their MELD scores. This finding has the
potential to change current practices and policies of many
transplant programs, which refuse to transplant a patient
with obesity. Our findings suggest that for these patients,
their MELD scores should be taken into consideration before denying their LT.
We also need to note that BMI is a measure incorporating
patients' height and weight, but it does not capture body fat
distribution or body shape. Nonetheless, it is one of the least
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expensive measures used in population health studies,39 such
as this study. Several smaller studies have used computed tomography imaging to measure patients' pretransplant body
composition and its association with posttransplant outcomes.50 DiMartini et al51 (n = 338) found that muscle mass
based on the pretransplant computed tomography data is a
significant predictor of post-LT survival in men and that
62% of the patients with a BMI of 25 or greater were cachectic, compared with 80% of the patients with a BMI of 18.5
to 24.9. Englesbe et al52 (n = 163) found that pretransplant
central sarcopenia determined by computerized tomography
scans of the psoas muscle strongly correlates with post-LT
mortality, whereas Jeon et al53 (n = 145) demonstrated that
pretransplant sarcopenia in LT patients is marginally significantly associated with longer survival.
Our study is the first to closely examine the relationship
between BMI and overall survival after LT and identify
BMI ranges at transplant associated with the best survival
outcome in patients undergoing LT in the era of postinstitution
of the MELD system, using a large database. However, our
study has several limitations that should be noted. First, like
all other studies using the OPTN database, this study is retrospective and uses only those variables available in this database. However, this database offers a large sample size that
allows us to identify statistically significant associations.
Second, the use of BMI at LT (or at listing) might not reflect
a patient’s true body weight as some of the patients could
have extensive peripheral edema or ascites,5 although we
have controlled for patients’ ascites at LT. This could be a
reason for no association in the relationship of BMI and
overall mortality in the highest MELD category. Third, selection bias could confound our analyses as well as studies using
this database due to current practices of many transplant
programs, which refuse LT in patients with a BMI of 40 or
greater. Lastly, we have not found a better way to categorize
MELD scores, which provides more clinical insights about
this association. Future studies can explore this.
CONCLUSIONS
Our study provides evidence that obesity in LT patients is
not necessarily associated with higher posttransplantation
mortality. Current policies about whether a patient is eligible
for LT should be reevaluated and should consider patient’s
BMI along with their MELD category to determine their survival likelihood.
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